报价延迟最少15分钟:2025/10/22 05:31 EDT
盘前时段
|
||||
|
1.96 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-10.13/2.06
|
|
企业价值
52.73M
|
| 资产负债 |
|
每股账面净值
-8.24
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
32.11M
|
|
每股收益
8.02
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/10/22 05:31 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. |
